NCT07361705 2026-01-23Zorifertinib With Osimertinib for NSCLC With Meningeal ProgressionAlpha Biopharma (Jiangsu) Co., Ltd.Phase 1 Not yet recruiting42 enrolled
NCT06319950 2024-03-20High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain MetastasesTaizhou HospitalPhase 2 Not yet recruiting255 enrolled